Clinical Trials Logo

Influenza Viral Infections clinical trials

View clinical trials related to Influenza Viral Infections.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05794412 Active, not recruiting - Clinical trials for SARS-CoV-2 Infection

Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

MIViral
Start date: January 10, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms: - Cough - Fever - Tired - Sore throat - Difficulty breathing - Respiratory distress - Headache - Loss (or alteration) of smell - Loss (or alteration) of sense of taste - Myalgias - Chills - Subjective fever - Pink sputum (or coughing up blood) - Thoracic pain - Runny nose - Abdominal pain - Nausea - Vomiting - Diarrhea - Constipation - Irritated or watery eyes - Rashes - Other

NCT ID: NCT04998344 Active, not recruiting - Clinical trials for Influenza Viral Infections

An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh

FluEffect
Start date: April 7, 2021
Phase: Phase 4
Study type: Interventional

Annually influenza is a leading cause of severe disease and mortality particularly in young children <5 years old and pregnant women in the low and middle-income countries (LMICs) and both groups are prioritised for vaccination by the World Health Organisation (WHO). In Bangladesh, influenza is responsible for 10% of all childhood pneumonias and 9% of all death. Maternal influenza is associated with an increased risk of hospitalisation and foetal malformation. Influenza is a vaccine preventable disease, however, in most LMICs influenza vaccination is not part of the vaccination programme. This study will evaluate the effectiveness of inactivated influenza vaccine against influenza illness among pregnant women and children in Bangladesh. Influenza vaccine has not yet been studied as combined immunization strategy in a cluster randomized trial. This study is a community-based randomised trial in both pregnant women and young children to assess the impact of inactivated influenza vaccine in preventing influenza in the community as well as population level impact by both direct and indirect effect of vaccination.

NCT ID: NCT01666782 Active, not recruiting - Cancer Clinical Trials

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

IMMUNE
Start date: August 2012
Phase: Phase 2
Study type: Interventional

The safety and immunogenicity of high dose influenza vaccine has not been studied in young patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and safety of high dose influenza to standard dose influenza vaccine in adult oncology patients who are younger than 65 years old receiving chemotherapy.